While BRAF-inhibitors such as vemurafenib have produced impressive response rates of approximately 60–80% in patients with BRAF-mutant metastatic malignant melanoma [20], vemurafenib is apparently much less efficient in BRAF-mutant CRC [21, meeting abstract]. The gene discussed is BRAF; the disease is metastatic melanoma.